Intended for healthcare professionals

  1. Research
  2. Randomised, double...
  3. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial
Papers

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

BMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7245.1297 (Published 13 May 2000) Cite this as: BMJ 2000;320:1297

Related articles

See more

Cited by...

  • Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study
  • Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD
  • Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait
  • Low serum free light chain is associated with risk of COPD exacerbation
  • Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD
  • Impact of smoking status on the efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review
  • Novel Type 2-high gene clusters associated with corticosteroid sensitivity in COPD
  • Treatment with inhaled {alpha}1-antitrypsin: a square peg in a round hole?
  • New therapeutic targets for the prevention of infectious acute exacerbations of COPD: role of epithelial adhesion molecules and inflammatory pathways
  • Effect of long-term corticosteroid treatment on microRNA and gene-expression profiles in COPD
  • Tiotropium discontinuation in patients with early-stage COPD: a prospective observational cohort study
  • Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box
  • Research highlights from the 2018 European Respiratory Society International Congress: airway disease
  • What is early COPD and why is it important?
  • Comparison of patient-reported outcomes during acute exacerbations of chronic obstructive pulmonary disease
  • Inhaler Training Delivered by Internet-Based Home Videoconferencing Improves Technique and Quality of Life
  • Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study
  • Are inhaled corticosteroids increasing the "load" for some patients with COPD?
  • Run-in bias in randomised trials: the case of COPD medications
  • Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary
  • Blood eosinophil count: a biomarker of an important treatable trait in patients with airway disease
  • Blood eosinophils as a marker of response to inhaled corticosteroids in COPD
  • An official American Thoracic Society/European Respiratory Society statement: research questions in COPD
  • An official American Thoracic Society/European Respiratory Society statement: research questions in COPD
  • Inhaled corticosteroids in COPD: the clinical evidence
  • The WISDOM of inhaled corticosteroids in COPD
  • Inhaled Corticosteroids Do Not Influence the Early Inflammatory Response and Clinical Presentation of Hospitalized Subjects With COPD Exacerbation
  • Early intervention with tiotropium in Chinese patients with GOLD stages I-II chronic obstructive pulmonary disease (Tie-COPD): study protocol for a multicentre, double-blinded, randomised, controlled trial
  • Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity
  • Umeclidinium in patients with COPD: a randomised, placebo-controlled study
  • Long-term macrolide treatment for chronic respiratory disease
  • Smoking cessation and COPD
  • Inhaled corticosteroids for chronic obstructive pulmonary disease
  • Variability of sputum inflammatory mediators in COPD and {alpha}1-antitrypsin deficiency
  • The acute effect of budesonide/formoterol in COPD: a multi-slice computed tomography and lung function study
  • Validity of an automated telephonic system to assess COPD exacerbation rates
  • Beyond corticosteroids: future prospects in the management of inflammation in COPD
  • The role of small airways in obstructive airway diseases
  • Prevalence of airflow limitation among employees in Norwegian smelters: a longitudinal study
  • Treatment of COPD: the sooner the better?
  • Family increases: UPLIFT(R) first maintenance subgroup analysis
  • Mucoactive therapy in COPD
  • Prevention of exacerbations of COPD with pharmacotherapy
  • Defective macrophage phagocytosis of bacteria in COPD
  • Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD
  • Recent improvement in long-term survival after a COPD hospitalisation
  • Use of inhaled budesonide for 1 year does not increase risk of pneumonia in patients with chronic obstructive pulmonary disease
  • Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD
  • Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence
  • Inhaled corticosteroids in COPD: a case in favour
  • Inhaled corticosteroids in COPD: the case against
  • A woman attending for routine review of her chronic obstructive pulmonary disease
  • Targeting Nrf2 with the triterpenoid CDDO- imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice
  • Fluticasone propionate reduces bacterial airway epithelial invasion
  • Recent advances in exacerbations of COPD
  • Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited
  • Methodological issues in therapeutic trials of COPD
  • Approach to chronic obstructive pulmonary disease in primary care
  • Drugs (including oxygen) in severe COPD
  • Outcomes for COPD pharmacological trials: from lung function to biomarkers
  • Interleukin-18 production and pulmonary function in COPD
  • The Role of I{kappa}B Kinase 2, but Not Activation of NF-{kappa}B, in the Release of CXCR3 Ligands from IFN-{gamma}-Stimulated Human Bronchial Epithelial Cells
  • Premature discontinuation of patients: a potential bias in COPD clinical trials
  • Where current pharmacological therapies fall short in COPD: symptom control is not enough
  • Systemic inflammation and decline in lung function in a general population: a prospective study
  • Exacerbations of chronic obstructive pulmonary disease
  • Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD
  • Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial
  • What is (and what is not) a COPD exacerbation: thoughts from the new GOLD guidelines
  • Impacting patient-centred outcomes in COPD: exacerbations and hospitalisations
  • Effect of primary-care spirometry on the diagnosis and management of COPD
  • Inhaled corticosteroids and mortality in COPD.
  • Can early diagnosis and effective management combat the irresistible rise of COPD?
  • Inhaled corticosteroids and mortality in COPD.
  • Predictors of COPD symptoms: does the sex of the patient matter?
  • Differential Genome Contents of Nontypeable Haemophilus influenzae Strains from Adults with Chronic Obstructive Pulmonary Disease
  • Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment
  • Efficacy and Safety of Inhaled Corticosteroids in Patients With COPD: A Systematic Review and Meta-Analysis of Health Outcomes
  • COPD exacerbations {middle dot} 4: Prevention
  • Increasing COPD awareness.
  • COPD: an inhaled corticosteroid-resistant, oral corticosteroid-responsive condition.
  • C-reactive protein in patients with COPD, control smokers and non-smokers
  • Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD
  • Inhaled corticosteroids in COPD: a light at the end of the tunnel?
  • Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease
  • Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
  • Relationship between respiratory symptoms and medical treatment in exacerbations of COPD
  • Bronchodilator response in the lung health study over 11 yrs
  • Exacerbations in {alpha}1-antitrypsin deficiency
  • Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial
  • COPD: current therapeutic interventions and future approaches
  • Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004
  • Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease
Back to top